Clinical Trials Browser

Phase 2 × Has announcements × 30 days × Clear all

NCT02601313 2026-03-18

ZUMA-2

Phase 2 Completed

105 enrolled 33 charts 2 FDA

Lymphoma, Mantle-Cell

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT04484142 2026-03-17

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Phase 2 Completed

137 enrolled 9 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04634552 2026-03-17

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT04640623 2026-03-13

SunRISe-1

Phase 2 Active not recruiting

220 enrolled 1 FDA

Urinary Bladder Neoplasms

NCT04557098 2026-03-12

MajesTEC-1

Phase 2 Active not recruiting

194 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04589845 2026-03-06

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT04924075 2026-02-24

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT02981628 2026-02-23

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

80 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03363373 2026-02-19

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Phase 2 Recruiting

122 enrolled 2 FDA

Neuroblastoma

NCT03332017 2026-02-18

ROSEWOOD

Phase 2 Completed

217 enrolled 23 charts 1 FDA

Lymphoma, Follicular